Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Autor: Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David H Adams, Lisa Kerr, Chin Lee, Catherine L Shuler, Mark Genovese, Khalid Ahmed, Jeffrey Alper, Nichol Barkham, Ralph E. Bennett, Francisco Javier Blanco García, Ricardo Blanco Alonso, Howard B. Blumstein, Michael S. Brooks, Gerd-Rüdiger Burmester, Patricia Cagnoli, Paul H. Caldron, Alain Cantagrel, Der-Yuan Chen, Melvin A. Churchill, Christine E. Codding, Peter M.G. Deane, Jose Del Giudice, Atul A. Deodhar, Rajat K. Dhar, Eva Dokoupilova, Rita M. Egan, Andrea Everding, Eva Galíndez, David H. Goddard, Alice Gottlieb, Philippe Goupille, Robert M. Griffin, Ramesh C. Gupta, Stephen Hall, Kalpita Hatti, Mary P. Howell, Yu-Huei Huang, Ramina Jajoo, Namieta M. Janssen, Uta Kiltz, Alan J. Kivitz, Steven J. Klein, Mariusz P. Korkosz, Roshan Kotha, Joel M. Kremer, Cummins Lue, José Luis Marenco de la Fuente, Helena Marzo-Ortega, Jordi Gratacós Masmitja, Philip J. Mease, Pier Luigi Meroni, Eric C. Mueller, Anupama C. Nandagudi, Antonio Fernández-Nebro, Clark M. Neuwelt, Ana Maria Orbai, Meera R. Oza, Deborah L. Parks, Debendra Pattanaik, Maria E. Rell-Bakalarska, David Rosmarin, Euthalia Roussou, Anna I. Rychlewska-Hanczewksa, David H. Sikes, Michael T. Stack, Prashanth Sunkureddi, Hasan Tahir, Diamant Thaçi, Tsen-Fang Tsai, Anthony M. Turkiewicz, Leonore Unger, Raúl Veiga Cabello, Ulf Wagner, Cheng-Chung Wei, Alvin F. Wells, Peter Youssef, Agnieszka Zielinska

Publikováno v: Lancet (London, England). 389(10086)

Patients who have had inadequate response to tumour necrosis factor inhibitors have fewer treatment options and are generally more treatment refractory to subsequent therapeutic interventions than previously untreated patients. We report the efficacy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e86bed9c822e2b158c34f88e2aa99b8
https://pubmed.ncbi.nlm.nih.gov/28592895

Early-life risk factors and allergic rhinitis: Comparing European and US data

Autor: Allison Clare Ramsey, Peter M.G. Deane

Publikováno v: Journal of Allergy and Clinical Immunology. 128:824-825

Allergic rhinitis has been shown to affect 3% to 19% of subjects in various epidemiologic studies of different populations. Eighty percent of those with allergic rhinitis experience symptoms by the age of 20 years, and 40% have symptoms by the age of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b9b1bcd4de6953df10c033c02da10f
https://doi.org/10.1016/j.jaci.2011.07.037